Close

FUJIFILM Irvine Scientific Announces Construction of a New Cell Culture Media Manufacturing Site in Europe

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Top Books Every Aspiring Pharmacist Should Read

Foundations That Shape the Profession Every pharmacist begins with a...

Cryogenic Identification Solutions for Pharma Supply Chains

Maintaining Track-and-Trace Integrity in Extreme Temperature Environments The pharmaceutical industry's...

Transforming Pharma Cold Chain Using IoT Real-Time Tracking

Transforming Pharmaceutical Cold Chain Through Connected Intelligence The pharmaceutical industry...

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

FUJIFILM Irvine Scientific, Inc., a global leader in the innovation, development, and manufacture of cell culture media, announced plans to open a third manufacturing facility located in Tilburg, Netherlands. The company currently has sites in the United States and Japan. Fujifilm’s investment in this project demonstrates its commitment to accelerate development in bioproduction, and cell and gene therapy markets.

The facility will occupy a 250,000 square foot building within FUJIFILM Manufacturing Europe B.V., one of the largest Fujifilm production centers outside of Japan. The space will support cGMP manufacturing of animal component-free, dry powder media, liquid media, and downstream bioprocessing liquids, thereby adding additional production capacity for FUJIFILM Irvine Scientific of 320,000 Kg/year for dry powder, and 470,000 L/year for liquids. Water for Injection (WFI) will also be manufactured on the premises.

“The biopharmaceutical market is growing at a high rate, and cell therapies are moving into clinical trials and commercialization at fast pace. The company’s current capacity is >1,000,000 Kg/year of dry powder, but it is imperative that we exceed production requirements of customers worldwide, as well as meet our European customer demand for regional support,” said Yutaka Yamaguchi, CEO, FUJIFILM Irvine Scientific. “Building a third, world-class cGMP manufacturing facility to serve as a European hub will enable us to better provide customers with rapid, reliable supply of products.”

Work on the new manufacturing site has begun and it is expected to be commissioned in the second half of 2021.

Latest stories

Related stories

Top Books Every Aspiring Pharmacist Should Read

Foundations That Shape the Profession Every pharmacist begins with a...

Cryogenic Identification Solutions for Pharma Supply Chains

Maintaining Track-and-Trace Integrity in Extreme Temperature Environments The pharmaceutical industry's...

Transforming Pharma Cold Chain Using IoT Real-Time Tracking

Transforming Pharmaceutical Cold Chain Through Connected Intelligence The pharmaceutical industry...

LOTTE BIOLOGICS Enters Contract Manufacturing Collaboration

LOTTE BIOLOGICS, on September 1, 2025, announced that it...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back